Bill Text — Aug 2, 2012
This bill’s text is now available.
GovTrack Insider, our Kickstarter-backed work to summarize bills in Congress, has resumed. Here’s what we’ve been up to:
Aug 2, 2012
112th Congress, 2011–2013
This bill was introduced on August 2, 2012, in a previous session of Congress, but was not enacted.
Senator from Vermont
Read Text »
Last Updated: Aug 2, 2012
Length: 7 pages
A bill to eliminate requirements to undertake duplicative clinical testing of new pharmaceutical drugs, vaccines, biological products, or medical devices, when such duplication is inconsistent with relevant ethical norms.
The bill’s title was written by its sponsor.
Earlier Version — Introduced
This activity took place on a related bill, S. 3921 (111th).
This is the first step in the legislative process.
This is a Senate bill in the United States Congress (indicated by the “S.” in “S. 3506”). A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
The committee chair determines whether a bill will move past the committee stage.
There have been no roll call votes related to this bill.
Click a format for a citation suggestion:
Civic Impulse. (2016). S. 3506 — 112th Congress: Ethical Pathway Act of 2012. Retrieved from https://www.govtrack.us/congress/bills/112/s3506
“S. 3506 — 112th Congress: Ethical Pathway Act of 2012.” www.GovTrack.us. 2012. February 13, 2016 <https://www.govtrack.us/congress/bills/112/s3506>
|title=S. 3506 (112th)
|accessdate=February 13, 2016
|author=112th Congress (2012)
|date=August 2, 2012
|quote=Ethical Pathway Act of 2012